MRgFUS for the treatment of recurrent bone sarcomas
Research type
Research Study
Full title
Magnetic Resonance guided Focused Ultrasound (MRgFUS) for the treatment of recurrent bone sarcomas.\n
IRAS ID
217135
Contact name
Jonathan/D Stevenson
Contact email
Sponsor organisation
Royal Orthopaedic Hospital
Duration of Study in the UK
0 years, 11 months, 30 days
Research summary
Primary bone tumours are extremely rare tumours which may recur in up to 27% of cases. In locally recurrent bone sarcomas, there are limited management options other than surgery, radiotherapy or invasive radio-frequency ablation. Some patients may have disease that would involve morbid surgery, or have previously received radiotherapy and have exceeded the local tissue toxicity for further radiotherapy. Radiofrequency ablation is invasive and requires the insertion of a probe percutaneously under general anaesthesia. Where the treatment intent is palliative, the morbidity of invasive procedures must be balanced against the potential symptomatic improvements.\n\nMagnetic resonance guided focused ultrasound (MRgFUS) may offer a non-invasive ablative technique for locally recurrent bone sarcomas, particularly where other salvage therapies may be contraindicated. MRgFUS has previously been used successfully to treat uterine fibroids, back pain, bone metastases, prostate cancer and fibromatosis. It is CE and FDA approved to treat metastatic bone tumours to improve pain and increase bone density. \n
REC name
North West - Greater Manchester West Research Ethics Committee
REC reference
16/NW/0866
Date of REC Opinion
17 Jan 2017
REC opinion
Further Information Favourable Opinion